Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 30 results found. Search for [ Herceptin ]

Results 1 to 21 of 30
BusinessToday.In
December 3, 2019
Ogivri will be launched at a competitive discount for customers to help ensure increased access to treatment for thousands of HER2-positive breast and gastric cancer patients, said Biocon


BusinessToday.In
December 2, 2019
Reliance Industries stock will remain in focus as RIL is seen as a major beneficiary after Jio announced tariff hike on Sunday.


E Kumar Sharma
New Delhi, November 25, 2019
A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?


PTI
May 22, 2019



PTI
May 17, 2019



E Kumar Sharma
January 25, 2019
Biocon reports robust growth across all business segments: Biologics, small molecules, branded formulations and research services


PB Jayakumar
New Delhi, January 9, 2019
Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide


PB Jayakumar
December 19, 2018
Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.


PTI
December 19, 2018



PTI
April 3, 2018



PTI
January 10, 2018



PTI
January 10, 2018



PTI
January 10, 2018



BusinessToday.in
New Delhi, December 4, 2017
After a long search, Infosys named Salil S Parekh as its new CEO and Managing Director.


PTI
December 2, 2017
Ogivri is the first United States Food and Drug Administration (USFDA) approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the US, the two companies said in a joint statement.


by E. Kumar Sharma
Delhi, December 26, 2016
Tech-savvy health care is making a difference to both the well-off and those with limited resources and access.


By E. Kumar Sharma
Delhi, July 23, 2016
Indian drug makers are slugging it out with Big Pharma over launch of biosimilars. Will they be able to hold their fort in this emerging space?


P.B. Jayakumar
March 5, 2015
The US is mounting pressure on India to agree to its terms in pharma IP protection. How long can India resist?


E. Kumar Sharma
May 31, 2014
In the seven years since, Mylan Inc has invested around $3 billion on acquisitions in India. It now regards India not just as a global sourcing hub, but also as a market.


E. Kumar Sharma
February 7, 2014
Roche has sought an injunction against two pharma companies - the Bangalore based Biocon and US-based Mylan. The two companies have launched a co-developed biosimilar of the drug Herceptin, which treats certain types of breast cancers. Formerly, Roche held the patent for Herceptin, but unexpectedly gave it up last year.


PAGES 1 OF 2  12